EUCTR2006-002486-39-FR进行中（未招募）1 期
A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer
- 入组人数
- 310
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males/Female subjects aged = 18 years
- •2. Females of childbearing potential must not be lactating, have a negative serum beta-HCG pregnancy test, be surgically sterile or be practicing an effective form of contraception. Acceptable methods of contraception are as follows:
- •a. Hormonal (oral, injectable or transdermal contraceptives).
- •b. Barrier method with spermicide.
- •c. Intrauterine device (IUD).
- •d. Complete abstinence may be considered acceptable, but must first be discussed on a case-by-case basis with the Pfizer Medical Director and Pfizer Clinical Monitor prior to any screening tests for the study.
- •3. The patient must have a malignant, solid tumor with that has been diagnosed as having metastasized to bone, and must have moderate to severe pain secondary to the bone metastasis. The patient should also be able to identify a reference site for pain, if possible, or rate their total body pain due to bone metastases if a specific lesion cannot be identified. Radiographic or scintographic confirmation of site of the painful bone metastases is required.
- •4. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study entry.
- •5. The patient’s mental status is sufficient to complete efficacy and tolerability scales and assessments.
- •6. Subject is willing and able to comply with scheduled visits, treatment plan, screening laboratory tests and other trial procedures.
- •7. Subject must have a pain score of at least 40mm on the 100mm Patient Assessment of Pain Visual Analogue Scale at Screening (Visit 1).
- •8. The patient has a performance status score of 0-2 (inclusive) as measured by the ECOG.
- •9. Life expectancy = 3 months from start of the study.
- •10. Creatinine Clearance =30mL/min as calculated by the Cockcroft-Gault equation (See Protocol Appendix 2).
- •11. Total white blood cell count > 1500/mm3; platelet count = 50 x103/mm3.
- •12. If applicable, stable chemotherapy treatment initiated more than one month prior to study start with the presence of significant moderate to severe pain and no signs of improvement in pain during the past month.
- •13. If applicable, radiotherapy or radiopharmaceutical treatment for bone metastases initiated = 15 days prior to study start with the presence of significant moderate to severe pain and no signs of improvement in pain since treatment was initiated.
- •14. If applicable, stable bisphosphonate therapy initiated more than two months prior to study start with the presence of significant moderate to severe pain and no signs of improvement in pain during the past month.
- •15. If applicable, subjects taking the following stable concomitant medications but still experiencing significant pain:
- •a. =One month stable doses of TCAs, antidepressants, but still experiencing moderate to severe pain
- •b. = 2 weeks stable doses corticosteroids, NSAIDs, paracetamol but still experiencing moderate to severe pain
- •c. = One month stable use of hypnotics/sedatives such as zopiclone, eszopiclone, ketazolam, zolpidem, zaleplon, triazolam, or rozerem. Dosing frequency of 3-7 times/ week is considered stable
- •d. =One month stable use of benzodiazepines such as alprazolam, clonazepam, diazepam, flurazepam, lorazepam, midazolam, quazepam, triazolam, and temazepam,
- •e. =One month stable hormone or anti-hormone therapy but still experiencing moderate to severe pain a
排除标准
- •1. Participation in previous clinical trials for pregabalin.
- •2. A previous history of intolerance or hypersensitivity to pregabalin, gabapentin or drugs with similar chemical structure.
- •3. Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to screening.
- •4. Illiterate or unable to complete subject-rated assessment scales.
- •5. The patient has back pain that, in the clinical judgment of the investigator, is related to mechanical or radicular causes.
- •6. The patient who has undergone diagnostic or therapeutic invasive interventions (angiography, biopsy, surgery) less than 15 days prior to study start that would impact their assessment of pain at the reference pain site or area, in the opinion of the investigator.
- •7. Methadone, antiepileptic drugs, current gabapentin or pregabalin use, or the initiation of analgesic therapies during the trial.
- •8. The patient has a physical or mental inability to answer question and comply with treatment protocol (such as an inability to swallow tablets or tolerate oral medication, or intractable nausea and vomiting).
- •9. The patient has a history of significant alcohol, analgesic or narcotic substance abuse within 6 months prior to screening as defined by DSM-IV-TR® criteria.
- •10. The patient has known seizure disorders = for 6 months prior to screening.
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82